5 results about "Oleanolic acid" patented technology

The application provides a kind of Jinguangdancao extract (tablet) fingerprint detection method, comprising the following steps: A) taking test sample raw material and being pretreated, obtaining the liquid to be measured;The pretreatment mode includes using solvent to dissolve, extraction;B) the liquid to be measured is determined using high performance liquid chromatography-evaporation light scattering method, and the HPLC-ELSD fingerprint of Jinguangdancao extract (tablet) is obtained;High performance liquid chromatography chromatographic conditions are as follows: column is C18 column;Mobile phase A is acetonitrile solution, mobile phase B is 0.1% formic acid aqueous solution, gradient elution;The application uses high performance liquid chromatography-evaporation light scattering method, selects acetonitrile-0.1% formic acid aqueous solution as mobile phase for gradient elution, with ursolic acid, oleanolic acid, β-amyrin, α-amyrin, friedelinone as reference, establishes the fingerprint detection method of Jinguangdancao extract (tablet), and the scientificity and internal quality of Jinguangdancao extract (tablet) are evaluated as a whole.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

The present application relates to the field of cosmetics, especially to an anti-aging essence and a preparation device, which is composed of A phase, B phase, C phase and D phase, and the components of each phase are as follows according to weight percentage: A phase: deionized water 16.15%, rose hydrolat 18.00%, propylene glycol 5.00%, glycerol 4.00%, xanthan gum 0.15%, carbomer 940 0.10%, panthenol (vitamin B5) 2.00%, boswelia (30% aqueous solution) 10.00%, ikedoin 2.00%, nicotinamide 2.00%, sodium hyaluronate compound 0.50%; B phase: polyglyceryl-6 distearate 1.20%, squalane 3.00%, isononyl isononanoate 2.00%, octyldodecanol 5.00%, rosehip oil 0.50%, argan oil 0.50%, ceramide compound powder 0.50%, cholesterol 0.30%, free fatty acid (C18-C22) 0.20%, Transcutol P 4.00%, oleanolic acid (ligustrum lucidum extract) 0.50%, plant extract compound liquid 5.00%, ergothioneine 0.30%. The advantages are that the active ingredient utilization rate is improved, the efficacy is comprehensive and the synergistic effect is strong, and the preparation device can make the mixing of each component more uniform, greatly improving the mixing efficiency.

This invention provides a CYP716 gene, protein, and applications for catalyzing the oxidation of β-amyrin at the C22α and C28 positions, belonging to the field of biotechnology. The CYP716 gene includes either CYP716BX1 (nucleotide sequence as shown in SEQ ID No. 1) or CYP716BX2 (nucleotide sequence as shown in SEQ ID No. 2). Studies have shown that CYP716BX1 and CYP716BX2 are isoenzymes, both capable of catalyzing the oxidation of β-amyrin at the C22α and C28 positions to 22α-hydroxy-kapogonadiol or 22α-hydroxy-oleanolic acid, and also capable of catalyzing the oxidation of 21β-hydroxy-β-amyrin at the C22α and C28 positions to 21β,22α-dihydroxy-kapogonadiol. This invention can provide key gene elements for the synthetic biology research of cyrimyl alcohol-type triterpenoids.

A COMPOSITION FOR TREATING KERATIN MATERIAL AND METHODS THEREOF The present disclosure provides a composition (A) comprising: a. oleanolic acid, its salts, solvates, or their mixtures thereof; b. ursolic acid, its salts, solvates, or their mixtures thereof; c. betulinic acid, its salts, solvates, or their mixtures thereof; and d. micromeric acid, its salts, solvates, or their mixtures thereof. The present disclosure further provides a rosemary extract and a composition (B). The present disclosure also provides a process for preparing the composition (A), the extract and methods thereof.